Pre-IPO Mirxes Holding (PHIP Updates) - Some Points Worth the Attention
GASTROClear faces limited clinical application due to lack of recognition,leading to lower-than-expected penetration.IPO pricing is expensive.We...
768 Views
ECM Weekly (19 May 2025) - CATL, Hengrui, Green Tea, SMPP, Unisound, Renesas, Genda, GMO, PayTM
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
787 Views
Mirxes IPO: Valuation Without Sensible Fundamentals
Singapore biotech company Mirexes launches IPO in Hong Kong to raise up to $139m, but little fundamentals support the valuation, even in blue sky...
1.3k Views
Mirxes Pre-IPO: Challenges for Mass Adoption Become Clearer
Mirxes files updated prospectus for Hong Kong listing, expanding clinical trial plans but facing challenges in achieving blockbuster-level success.
770 Views
Mirxes Pre-IPO: Early Signs of Commercialization Challenges
We look at fundamentals of Mirxes, including its key products, commercialization and shareholders, as it is planning to list in Hong Kong.
901 Views